Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 2/20 | 0.34 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700587 | 0.93 | PLA2G10 (0.38) | PLA2G10PLA2G5CHRM2CHRM4CHRM1 | |
| SCHEMBL12092237 | 0.93 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL30069168 | 0.88 | PLA2G10 (0.35) | PLA2G10PLA2G5CHRM2CHRM4CHRM1 | |
| SCHEMBL3690735 | 0.87 | PLA2G10 (0.37) | PLA2G10PLA2G5CHRM2CHRM4CHRM1 | |
| SCHEMBL12018082 | 0.85 | HTR4 (0.32) | PLA2G10PLA2G5HTR4 | |
| SCHEMBL18022129 | 0.83 | PLA2G10 (0.34) | PLA2G10PLA2G5CHRM2CHRM4CHRM1 | |
| SCHEMBL17173825 | 0.82 | HTR4 (0.32) | HTR4 | |
| SCHEMBL9610825 | 0.79 | VEGFA (0.39) | HTR4KDM4EALDH1A1 | |
| SCHEMBL15831754 | 0.79 | HSD17B10 (0.37) | PLA2G10PLA2G5CHRM2CHRM4CHRM1 | |
| SCHEMBL25355536 | 0.78 | WNT1 (0.39) | PLA2G10PLA2G5HTR4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140271465-A1 | MATRIX METALLOPROTEASE (MMP) TARGETED AGENTS FOR IMAGING AND THERAPY | MALLINCKRODT LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20120148492-A1 | BISPHOSPHONIC ACID DERIVATIVE AND COMPOUND THEREOF LABELED WITH RADIOACTIVE METAL NUCLIDE | FUJIFILM RI PHARMA CO., LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271465-A1 | MATRIX METALLOPROTEASE (MMP) TARGETED AGENTS FOR IMAGING AND THERAPY | MMP3, MMP26, MMP10 | PLA2G10 2707/4885PLA2G5 2658/4885CHRM2 4603/4885 |
| US-20120148492-A1 | BISPHOSPHONIC ACID DERIVATIVE AND COMPOUND THEREOF LABELED WITH RADIOACTIVE METAL NUCLIDE | PTH1R, SOST, BPGM | PLA2G10 4055/4885PLA2G5 3156/4885CHRM2 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.